Transthyretin Amyloid Cardiomyopathy Market
Transthyretin Amyloid Cardiomyopathy Market Size, Share & Industry Analysis, By Treatment Type (Pharmacological, Non-Pharmacological), By Drug Class (TTR Stabilizers, RNA-Targeting Therapies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The Transthyretin Amyloid Cardiomyopathy Market is projected to grow at a CAGR of 12.5% from 2024 to 2031. The market value is expected to rise from XX USD in 2024 to YY USD by 2031. North America currently dominates the market, with key metrics indicating strong growth in innovative treatment options and increasing awareness about this rare disease. The market is experiencing robust expansion driven by advancements in diagnostic technologies, rising prevalence of the disease, and growing investments in research and development of targeted therapies.
Transthyretin Amyloid Cardiomyopathy Market Dynamics:
Market Trend: Emergence of gene silencing therapies
The development and application of gene silencing drugs, particularly RNA interference (RNAi) therapy, are altering the treatment choices for transthyretin amyloid cardiomyopathy (ATTR-CM). These innovative medicines aim to reduce transthyretin protein production at the source, perhaps slowing or reversing disease progression. Recent clinical trials have produced promising results, with many gene silencing medicines lowering serum TTR levels and improving cardiac function. During phase 3 trials, a well-known pharmaceutical company discovered that its RNAi therapy reduced serum TTR levels in ATTR-CM patients by up to 80 percent. This trend is expected to continue as novel gene silencing drugs progress through late-stage clinical trials and may reach the market in the coming years.
Market Driver: Increasing diagnosis rates and awareness
The growing awareness of ATTR-CM among healthcare professionals and patients, combined with advancements in diagnostic technology, is driving market growth. In recent years, the use of non-invasive diagnostic tools such as nuclear scintigraphy and cardiac magnetic resonance imaging has expanded dramatically, allowing ATTR-CM to be identified earlier and more accurately. A multi-center study discovered that ATTR-CM diagnoses increased by 35% over the previous five years, owing to increasing awareness and diagnostic ability. Furthermore, patient advocacy organisations and medical associations have increased their efforts to educate the public and healthcare professionals about this rare condition, resulting in early interventions and a greater need for treatment choices.
Market Restraint: High cost of treatment
The high cost of novel ATTR-CM treatments creates a significant barrier to commercial expansion. New drugs, particularly gene silencing therapies and TTR stabilisers, are often expensive due to the lengthy development and manufacturing processes. For example, the annual cost of treatment with a top TTR stabiliser can exceed $250,000 per patient. This high cost may restrict access to therapy, especially in areas with weak healthcare systems or insufficient insurance coverage. The high cost of these drugs may place a strain on healthcare resources and affect reimbursement decisions, limiting the adoption of innovative treatments.
Segment Overview:
The TTR Stabilizers segment dominates the Transthyretin Amyloid Cardiomyopathy Market:
TTR Stabilisers presently account for about YY% of the Transthyretin Amyloid Cardiomyopathy market. This dominance stems from their shown efficacy in stabilising the transthyretin protein and delaying disease progression. TTR stabilisers were among the first targeted drugs approved for ATTR-CM, and they have demonstrated significant therapeutic benefits in terms of lower mortality and higher quality of life.
A recent long-term follow-up study from a major clinical trial revealed that patients treated with a leading TTR stabiliser experienced a 30% reduction in all-cause mortality over a 5-year period when compared to placebo. The overwhelming evidence has established TTR stabilisers as a critical component of ATTR-CM treatment.
TTR stabilisers have grown in popularity in developed countries, with prescription rates rising by YY% in North America and Europe over the last two years. This growth is being driven by more acceptance of both wild-type and hereditary ATTR-CM, as well as increased clinician knowledge with these drugs.
Regional Outlook:
Dominating Region: North America leads the Transthyretin Amyloid Cardiomyopathy Market
North America now controls the largest market share in the Transthyretin Amyloid Cardiomyopathy Market, accounting for more than YY% of total value. This dominance is attributable in part to the region's superior healthcare infrastructure, high levels of expertise, and rapid adoption of novel therapies.
The United States, in particular, has pioneered ATTR-CM research and therapy. In 2023, the US Food and Drug Administration (FDA) promptly approved two novel ATTR-CM medications, expanding patients' treatment options. This regulatory environment has prompted pharmaceutical companies to invest extensively in R&D and clinical trials in the region.
According to current data from the American Heart Association, the diagnosed prevalence of ATTR-CM in the United States has increased by 25% over the last three years, owing in part to improved screening and diagnostic capabilities. The rising prevalence has had a direct impact on regional market development.
Canada has also made significant progress in ATTR-CM care, with a national project commencing in 2024 to improve early detection and treatment access. This program intends to reduce diagnosis time by half while offering equal access to licensed medications across jurisdictions.
Competitive Intelligence:
Transthyretin Amyloid Cardiomyopathy is a highly competitive market, with only a few specialised pharmaceutical companies dominating. Market leaders have made significant investments in R&D to develop novel cures and expand the use of existing medications. For example, a well-known investor has pledged $500 million to ATTR-CM research over the next five years, with a focus on next-generation gene silencing technologies and combination medications.
Strategic partnerships and collaborations have shown to be beneficial strategy for businesses looking to strengthen their market position. Over the last year, three notable collaborations between pharmaceutical companies and academic institutions have occurred, with the goal of identifying new biomarkers for early ATTR-CM detection and developing personalised therapy approaches.
The top three players hold market shares ranging from YY% to YY%, with the leading company accounting for around 32% of the global market. According to financial data, the leading players' ATTR-CM portfolios have grown by an average of 15-20% per year over the last three years.
Looking ahead, organisations are concentrating on expanding their regional footprint, particularly in emerging areas where diagnostic rates are rapidly rising. Furthermore, there is an increasing emphasis on developing combination therapies that address many aspects of ATTR-CM pathophysiology, potentially providing patients with more comprehensive treatment choices.
Analyst Opinion:
The Transthyretin Amyloid Cardiomyopathy Market is predicted to grow rapidly due to scientific advances and improved disease awareness. One significant trend to watch is the possibility of synergy between diverse therapy techniques, such as combining TTR stabilisers with gene silencing therapies to improve clinical outcomes. Furthermore, identifying biomarkers for early detection and medication response monitoring has the potential to improve ATTR-CM therapy by allowing for more personalised and effective treatment options.
Major Players:
-
Pfizer Inc.
-
Alnylam Pharmaceuticals, Inc.
-
Ionis Pharmaceuticals, Inc.
-
Eidos Therapeutics, Inc. (BridgeBio Pharma)
-
Akcea Therapeutics, Inc.
-
Intellia Therapeutics, Inc.
-
Prothena Corporation plc
-
GlaxoSmithKline plc
-
Corino Therapeutics, Inc.
-
SOM Biotech SL
Key Developments:
-
In July 2023, Alnylam Pharmaceuticals received FDA approval for an additional application of their RNAi therapy, including the treatment of wild-type ATTR-CM.
-
February 2024: Pfizer released positive phase 3 trial results for its next-generation TTR stabiliser, exhibiting efficacy above the current level of therapy.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Pfizer Inc.
5.2. Alnylam Pharmaceuticals, Inc.
5.3. Ionis Pharmaceuticals, Inc.
5.4. Eidos Therapeutics, Inc. (BridgeBio Pharma)
5.5. Akcea Therapeutics, Inc.
5.6. Intellia Therapeutics, Inc.
5.7. Prothena Corporation plc
5.8. GlaxoSmithKline plc
5.9. Corino Therapeutics, Inc.
5.10. SOM Biotech SL (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Emergence of gene silencing therapies
6.1.2. Development of combination therapies
6.1.3. Focus on biomarker discovery for early detection
6.2. Market Drivers
6.2.1. Increasing diagnosis rates and awareness
6.2.2. Advancements in diagnostic technologies
6.2.3. Rising investments in R&D
6.3. Market Restraints
6.3.1. High cost of treatment
6.3.2. Limited awareness in developing regions
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY TREATMENT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Pharmacological
7.2. Non-Pharmacological
8. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. TTR Stabilizers
8.2. RNA-Targeting Therapies
8.3. Others
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Treatment Type:
-
Pharmacological
-
Non-Pharmacological
By Drug Class:
-
TTR Stabilizers
-
RNA-Targeting Therapies
-
Others
By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511